Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status
Titel:
Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status
Auteur:
Jayaram, A. Nowakowska, K. Mateo, J. Hernandez, T. Kumar, S. Fulton, B. Nava Rodrigues, D. Riisnaes, R. Zukiwski, A. Proniuk, S. Bexon, A.S. Bisaha, J. Bianchini, D. Zafeiriou, Z. Lopez, R.P. Tunariu, N. Pacey, S. Jones, R. de Bono, J. Sebastian Attard, G.